Subscribe for perks & to support LI

Your Interests & Preferences: Personalise your reading

Which best describes your role and/or interests?

I work in a law firm
I work for a company / in-house
I'm a litigator at the bar
I'm a law student
Aspiring law student
Save setting
Or click here to show more preferences...

I am interested in the following types of stories (uncheck to hide from frontpage)

Firms / In-House
Legal Education

Always show me: (overrides the above)

Exclusives & Editor's Picks

Website Look & Feel

Light Text on Dark Background

Save preferences

Note: Your preferences will be saved in your browser. You can always change your settings by clicking the Your Preferences button at the top of every page.

Reset preferences to defaults?

JSA, Rajani Singhania steer FIPB-free Japanese pharma buy after DIPP note

J Sagar Associates (JSA) advised the shareholders of Lilac Medicare on selling it off to Japan’s Tosoh Corporation and Singapore’s Tosoh Asia which were advised by Rajani Singhania & Partners.

JSA partner Sidharrth Shankar, senior associate Shantanu Jindel and associates Prakriti Jaiswal and Priyam Singh acted for Lilac.

Rajani partner Reena Grover acted for Tosoh.

This is a notable transaction in the pharma space, which did not require the approval of the Foreign Investment Promotion Board, after the Department of Industrial Policy and Promotion notified Press Note 2 of 2015, according to JSA’s press release.

The $7.5bn Tosoh is one of the largest chlor-alkali manufacturers in Asia, reported Business Standard.

Click to show 3 comments
at your own risk
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.
refresh Filter out low-rated comments. Show all comments. Sort chronologically
Like +2 Object -1 On call discussion 01 May 15, 09:09
Jindal Sahab, the great!
Reply Report to LI
Like +2 Object -1 Pharma Counsel 02 May 15, 20:56
Can you please elaborate why the FIPB approval wasnt required? PN 2 of 2015 exempted non compete in medical devices. It did not take away the requirement of FIPB approvalfor brownfield investment.
Reply Report to LI
Like +1 Object -0 Carma Phounsel 04 May 15, 20:23
Medical devices company.
Reply Report to LI

Latest comments